Universe Pharmaceuticals Inc. (NASDAQ: UPC) Stock Competitors & Peer Comparison
See UPC's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for UPC and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| UPC | $5.56 | -10.90% | 3.5M | -0.69 | -$8.06 | N/A |
| TAK | $17.45 | +2.53% | 55.5B | 12.55 | $1.39 | +3.61% |
| HLN | $10.03 | +0.00% | 44.2B | 25.11 | $0.40 | +1.76% |
| TEVA | $35.36 | +1.58% | 41.2B | 12.06 | $2.93 | N/A |
| VTRS | $16.43 | +0.86% | 19.1B | 6.52 | $2.52 | +2.90% |
| ITCI | $131.87 | +0.00% | 14B | -180.64 | -$0.73 | N/A |
| CTLT | $63.48 | +0.00% | 11.5B | -27.84 | -$2.28 | N/A |
| ELAN | $22.12 | -8.60% | 11B | 20.86 | $1.06 | N/A |
| RDY | $12.22 | +0.91% | 10.2B | 20.01 | $0.61 | +0.68% |
| LNTH | $100.95 | -0.12% | 6.6B | 16.97 | $5.95 | N/A |
Stock Comparison
Takeda Pharmaceutical Company Limited (NYSE: TAK)
UPC vs TAK Comparison August 2026
Universe Pharmaceuticals Inc. (NASDAQ: UPC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPC stands at 3.5M. In comparison, TAK has a market cap of 55.5B. Regarding current trading prices, UPC is priced at $5.56 on the NASDAQ, while TAK trades at $17.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPC currently has a P/E ratio of -0.69, whereas TAK's P/E ratio is 12.55. In terms of profitability, UPC's ROE is -0.03%, compared to TAK's ROE of +0.02%. Regarding short-term risk, UPC is more volatile compared to TAK. This indicates higher risk in terms of short-term price fluctuations for UPC.Check TAK's competition here
Haleon plc (NYSE: HLN)
UPC vs HLN Comparison August 2026
Universe Pharmaceuticals Inc. (NASDAQ: UPC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPC stands at 3.5M. In comparison, HLN has a market cap of 44.2B. Regarding current trading prices, UPC is priced at $5.56 on the NASDAQ, while HLN trades at $10.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPC currently has a P/E ratio of -0.69, whereas HLN's P/E ratio is 25.11. In terms of profitability, UPC's ROE is -0.03%, compared to HLN's ROE of +0.17%. Regarding short-term risk, UPC is more volatile compared to HLN. This indicates higher risk in terms of short-term price fluctuations for UPC.Check HLN's competition here
Teva Pharmaceutical Industries Limited (NYSE: TEVA)
UPC vs TEVA Comparison August 2026
Universe Pharmaceuticals Inc. (NASDAQ: UPC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPC stands at 3.5M. In comparison, TEVA has a market cap of 41.2B. Regarding current trading prices, UPC is priced at $5.56 on the NASDAQ, while TEVA trades at $35.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPC currently has a P/E ratio of -0.69, whereas TEVA's P/E ratio is 12.06. In terms of profitability, UPC's ROE is -0.03%, compared to TEVA's ROE of +0.09%. Regarding short-term risk, UPC is more volatile compared to TEVA. This indicates higher risk in terms of short-term price fluctuations for UPC.Check TEVA's competition here
Viatris Inc. (NASDAQ: VTRS)
UPC vs VTRS Comparison August 2026
Universe Pharmaceuticals Inc. (NASDAQ: UPC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPC stands at 3.5M. In comparison, VTRS has a market cap of 19.1B. Regarding current trading prices, UPC is priced at $5.56 on the NASDAQ, while VTRS trades at $16.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPC currently has a P/E ratio of -0.69, whereas VTRS's P/E ratio is 6.52. In terms of profitability, UPC's ROE is -0.03%, compared to VTRS's ROE of -0.03%. Regarding short-term risk, UPC is more volatile compared to VTRS. This indicates higher risk in terms of short-term price fluctuations for UPC.Check VTRS's competition here
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI)
UPC vs ITCI Comparison August 2026
Universe Pharmaceuticals Inc. (NASDAQ: UPC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPC stands at 3.5M. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, UPC is priced at $5.56 on the NASDAQ, while ITCI trades at $131.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPC currently has a P/E ratio of -0.69, whereas ITCI's P/E ratio is -180.64. In terms of profitability, UPC's ROE is -0.03%, compared to ITCI's ROE of -0.09%. Regarding short-term risk, UPC is more volatile compared to ITCI. This indicates higher risk in terms of short-term price fluctuations for UPC.Check ITCI's competition here
Catalent, Inc. (NYSE: CTLT)
UPC vs CTLT Comparison August 2026
Universe Pharmaceuticals Inc. (NASDAQ: UPC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPC stands at 3.5M. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, UPC is priced at $5.56 on the NASDAQ, while CTLT trades at $63.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPC currently has a P/E ratio of -0.69, whereas CTLT's P/E ratio is -27.84. In terms of profitability, UPC's ROE is -0.03%, compared to CTLT's ROE of -0.25%. Regarding short-term risk, UPC is more volatile compared to CTLT. This indicates higher risk in terms of short-term price fluctuations for UPC.Check CTLT's competition here
Elanco Animal Health Incorporated (NYSE: ELAN)
UPC vs ELAN Comparison August 2026
Universe Pharmaceuticals Inc. (NASDAQ: UPC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPC stands at 3.5M. In comparison, ELAN has a market cap of 11B. Regarding current trading prices, UPC is priced at $5.56 on the NASDAQ, while ELAN trades at $22.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPC currently has a P/E ratio of -0.69, whereas ELAN's P/E ratio is 20.86. In terms of profitability, UPC's ROE is -0.03%, compared to ELAN's ROE of -0.03%. Regarding short-term risk, UPC is more volatile compared to ELAN. This indicates higher risk in terms of short-term price fluctuations for UPC.Check ELAN's competition here
Dr. Reddy's Laboratories Limited (NYSE: RDY)
UPC vs RDY Comparison August 2026
Universe Pharmaceuticals Inc. (NASDAQ: UPC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPC stands at 3.5M. In comparison, RDY has a market cap of 10.2B. Regarding current trading prices, UPC is priced at $5.56 on the NASDAQ, while RDY trades at $12.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPC currently has a P/E ratio of -0.69, whereas RDY's P/E ratio is 20.01. In terms of profitability, UPC's ROE is -0.03%, compared to RDY's ROE of +0.09%. Regarding short-term risk, UPC is more volatile compared to RDY. This indicates higher risk in terms of short-term price fluctuations for UPC.Check RDY's competition here
Lantheus Holdings, Inc. (NASDAQ: LNTH)
UPC vs LNTH Comparison August 2026
Universe Pharmaceuticals Inc. (NASDAQ: UPC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPC stands at 3.5M. In comparison, LNTH has a market cap of 6.6B. Regarding current trading prices, UPC is priced at $5.56 on the NASDAQ, while LNTH trades at $100.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPC currently has a P/E ratio of -0.69, whereas LNTH's P/E ratio is 16.97. In terms of profitability, UPC's ROE is -0.03%, compared to LNTH's ROE of +0.23%. Regarding short-term risk, UPC is more volatile compared to LNTH. This indicates higher risk in terms of short-term price fluctuations for UPC.Check LNTH's competition here
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX)
UPC vs AMRX Comparison August 2026
Universe Pharmaceuticals Inc. (NASDAQ: UPC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPC stands at 3.5M. In comparison, AMRX has a market cap of 5.8B. Regarding current trading prices, UPC is priced at $5.56 on the NASDAQ, while AMRX trades at $18.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPC currently has a P/E ratio of -0.69, whereas AMRX's P/E ratio is 20.16. In terms of profitability, UPC's ROE is -0.03%, compared to AMRX's ROE of -3.27%. Regarding short-term risk, UPC is more volatile compared to AMRX. This indicates higher risk in terms of short-term price fluctuations for UPC.Check AMRX's competition here
Indivior Pharmaceuticals Inc (NASDAQ: INDV)
UPC vs INDV Comparison August 2026
Universe Pharmaceuticals Inc. (NASDAQ: UPC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPC stands at 3.5M. In comparison, INDV has a market cap of 4.8B. Regarding current trading prices, UPC is priced at $5.56 on the NASDAQ, while INDV trades at $38.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPC currently has a P/E ratio of -0.69, whereas INDV's P/E ratio is 10.64. In terms of profitability, UPC's ROE is -0.03%, compared to INDV's ROE of -2.16%. Regarding short-term risk, UPC is more volatile compared to INDV. This indicates higher risk in terms of short-term price fluctuations for UPC.Check INDV's competition here
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN)
UPC vs SUPN Comparison August 2026
Universe Pharmaceuticals Inc. (NASDAQ: UPC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPC stands at 3.5M. In comparison, SUPN has a market cap of 2.8B. Regarding current trading prices, UPC is priced at $5.56 on the NASDAQ, while SUPN trades at $47.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPC currently has a P/E ratio of -0.69, whereas SUPN's P/E ratio is 15.57. In terms of profitability, UPC's ROE is -0.03%, compared to SUPN's ROE of -0.10%. Regarding short-term risk, UPC is more volatile compared to SUPN. This indicates higher risk in terms of short-term price fluctuations for UPC.Check SUPN's competition here
Regencell Bioscience Holdings Limited (NASDAQ: RGC)
UPC vs RGC Comparison August 2026
Universe Pharmaceuticals Inc. (NASDAQ: UPC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPC stands at 3.5M. In comparison, RGC has a market cap of 2.7B. Regarding current trading prices, UPC is priced at $5.56 on the NASDAQ, while RGC trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPC currently has a P/E ratio of -0.69, whereas RGC's P/E ratio is -380.99. In terms of profitability, UPC's ROE is -0.03%, compared to RGC's ROE of -2.32%. Regarding short-term risk, UPC is more volatile compared to RGC. This indicates higher risk in terms of short-term price fluctuations for UPC.Check RGC's competition here
Bausch Health Companies Inc. (NYSE: BHC)
UPC vs BHC Comparison August 2026
Universe Pharmaceuticals Inc. (NASDAQ: UPC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPC stands at 3.5M. In comparison, BHC has a market cap of 2.3B. Regarding current trading prices, UPC is priced at $5.56 on the NASDAQ, while BHC trades at $6.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPC currently has a P/E ratio of -0.69, whereas BHC's P/E ratio is 1.59. In terms of profitability, UPC's ROE is -0.03%, compared to BHC's ROE of +0.89%. Regarding short-term risk, UPC is more volatile compared to BHC. This indicates higher risk in terms of short-term price fluctuations for UPC.Check BHC's competition here
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH)
UPC vs DCPH Comparison August 2026
Universe Pharmaceuticals Inc. (NASDAQ: UPC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPC stands at 3.5M. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, UPC is priced at $5.56 on the NASDAQ, while DCPH trades at $25.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPC currently has a P/E ratio of -0.69, whereas DCPH's P/E ratio is -11.58. In terms of profitability, UPC's ROE is -0.03%, compared to DCPH's ROE of -0.56%. Regarding short-term risk, UPC is more volatile compared to DCPH. This indicates higher risk in terms of short-term price fluctuations for UPC.Check DCPH's competition here
HUTCHMED (China) Limited (NASDAQ: HCM)
UPC vs HCM Comparison August 2026
Universe Pharmaceuticals Inc. (NASDAQ: UPC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPC stands at 3.5M. In comparison, HCM has a market cap of 2.2B. Regarding current trading prices, UPC is priced at $5.56 on the NASDAQ, while HCM trades at $12.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPC currently has a P/E ratio of -0.69, whereas HCM's P/E ratio is 4.69. In terms of profitability, UPC's ROE is -0.03%, compared to HCM's ROE of +0.01%. Regarding short-term risk, UPC is more volatile compared to HCM. This indicates higher risk in terms of short-term price fluctuations for UPC.Check HCM's competition here
Avadel Pharmaceuticals plc (NASDAQ: AVDL)
UPC vs AVDL Comparison August 2026
Universe Pharmaceuticals Inc. (NASDAQ: UPC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPC stands at 3.5M. In comparison, AVDL has a market cap of 2.1B. Regarding current trading prices, UPC is priced at $5.56 on the NASDAQ, while AVDL trades at $21.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPC currently has a P/E ratio of -0.69, whereas AVDL's P/E ratio is -1082.00. In terms of profitability, UPC's ROE is -0.03%, compared to AVDL's ROE of +0.05%. Regarding short-term risk, UPC is more volatile compared to AVDL. This indicates higher risk in terms of short-term price fluctuations for UPC.Check AVDL's competition here
Embecta Corp. (NASDAQ: EMBCV)
UPC vs EMBCV Comparison August 2026
Universe Pharmaceuticals Inc. (NASDAQ: UPC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPC stands at 3.5M. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, UPC is priced at $5.56 on the NASDAQ, while EMBCV trades at $33.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPC currently has a P/E ratio of -0.69, whereas EMBCV's P/E ratio is N/A. In terms of profitability, UPC's ROE is -0.03%, compared to EMBCV's ROE of -0.19%. Regarding short-term risk, UPC is more volatile compared to EMBCV. This indicates higher risk in terms of short-term price fluctuations for UPC.Check EMBCV's competition here
Dynavax Technologies Corporation (NASDAQ: DVAX)
UPC vs DVAX Comparison August 2026
Universe Pharmaceuticals Inc. (NASDAQ: UPC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPC stands at 3.5M. In comparison, DVAX has a market cap of 1.8B. Regarding current trading prices, UPC is priced at $5.56 on the NASDAQ, while DVAX trades at $15.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPC currently has a P/E ratio of -0.69, whereas DVAX's P/E ratio is -41.89. In terms of profitability, UPC's ROE is -0.03%, compared to DVAX's ROE of -0.10%. Regarding short-term risk, UPC is more volatile compared to DVAX. This indicates higher risk in terms of short-term price fluctuations for UPC.Check DVAX's competition here
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP)
UPC vs ANIP Comparison August 2026
Universe Pharmaceuticals Inc. (NASDAQ: UPC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPC stands at 3.5M. In comparison, ANIP has a market cap of 1.8B. Regarding current trading prices, UPC is priced at $5.56 on the NASDAQ, while ANIP trades at $78.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPC currently has a P/E ratio of -0.69, whereas ANIP's P/E ratio is 9.52. In terms of profitability, UPC's ROE is -0.03%, compared to ANIP's ROE of +0.19%. Regarding short-term risk, UPC is more volatile compared to ANIP. This indicates higher risk in terms of short-term price fluctuations for UPC.Check ANIP's competition here
Perrigo Company plc (NYSE: PRGO)
UPC vs PRGO Comparison August 2026
Universe Pharmaceuticals Inc. (NASDAQ: UPC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPC stands at 3.5M. In comparison, PRGO has a market cap of 1.8B. Regarding current trading prices, UPC is priced at $5.56 on the NASDAQ, while PRGO trades at $12.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPC currently has a P/E ratio of -0.69, whereas PRGO's P/E ratio is 5.13. In terms of profitability, UPC's ROE is -0.03%, compared to PRGO's ROE of -0.56%. Regarding short-term risk, UPC is more volatile compared to PRGO. This indicates higher risk in terms of short-term price fluctuations for UPC.Check PRGO's competition here
Taro Pharmaceutical Industries Ltd. (NYSE: TARO)
UPC vs TARO Comparison August 2026
Universe Pharmaceuticals Inc. (NASDAQ: UPC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPC stands at 3.5M. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, UPC is priced at $5.56 on the NASDAQ, while TARO trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPC currently has a P/E ratio of -0.69, whereas TARO's P/E ratio is 30.05. In terms of profitability, UPC's ROE is -0.03%, compared to TARO's ROE of +0.03%. Regarding short-term risk, UPC is more volatile compared to TARO. This indicates higher risk in terms of short-term price fluctuations for UPC.Check TARO's competition here
Harrow Health, Inc. (NASDAQ: HROW)
UPC vs HROW Comparison August 2026
Universe Pharmaceuticals Inc. (NASDAQ: UPC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPC stands at 3.5M. In comparison, HROW has a market cap of 1.5B. Regarding current trading prices, UPC is priced at $5.56 on the NASDAQ, while HROW trades at $40.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPC currently has a P/E ratio of -0.69, whereas HROW's P/E ratio is 449.33. In terms of profitability, UPC's ROE is -0.03%, compared to HROW's ROE of -0.34%. Regarding short-term risk, UPC is more volatile compared to HROW. This indicates higher risk in terms of short-term price fluctuations for UPC.Check HROW's competition here
Phibro Animal Health Corporation (NASDAQ: PAHC)
UPC vs PAHC Comparison August 2026
Universe Pharmaceuticals Inc. (NASDAQ: UPC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPC stands at 3.5M. In comparison, PAHC has a market cap of 1.4B. Regarding current trading prices, UPC is priced at $5.56 on the NASDAQ, while PAHC trades at $34.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPC currently has a P/E ratio of -0.69, whereas PAHC's P/E ratio is 11.70. In terms of profitability, UPC's ROE is -0.03%, compared to PAHC's ROE of +0.29%. Regarding short-term risk, UPC is more volatile compared to PAHC. This indicates higher risk in terms of short-term price fluctuations for UPC.Check PAHC's competition here
Alvotech (NASDAQ: ALVO)
UPC vs ALVO Comparison August 2026
Universe Pharmaceuticals Inc. (NASDAQ: UPC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPC stands at 3.5M. In comparison, ALVO has a market cap of 1.3B. Regarding current trading prices, UPC is priced at $5.56 on the NASDAQ, while ALVO trades at $3.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPC currently has a P/E ratio of -0.69, whereas ALVO's P/E ratio is -11.21. In terms of profitability, UPC's ROE is -0.03%, compared to ALVO's ROE of +0.35%. Regarding short-term risk, UPC is more volatile compared to ALVO. This indicates higher risk in terms of short-term price fluctuations for UPC.Check ALVO's competition here
Eton Pharmaceuticals, Inc. (NASDAQ: ETON)
UPC vs ETON Comparison August 2026
Universe Pharmaceuticals Inc. (NASDAQ: UPC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPC stands at 3.5M. In comparison, ETON has a market cap of 1.2B. Regarding current trading prices, UPC is priced at $5.56 on the NASDAQ, while ETON trades at $44.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPC currently has a P/E ratio of -0.69, whereas ETON's P/E ratio is -637.14. In terms of profitability, UPC's ROE is -0.03%, compared to ETON's ROE of -0.06%. Regarding short-term risk, UPC is more volatile compared to ETON. This indicates higher risk in terms of short-term price fluctuations for UPC.Check ETON's competition here
Cronos Group Inc. (NASDAQ: CRON)
UPC vs CRON Comparison August 2026
Universe Pharmaceuticals Inc. (NASDAQ: UPC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPC stands at 3.5M. In comparison, CRON has a market cap of 1.2B. Regarding current trading prices, UPC is priced at $5.56 on the NASDAQ, while CRON trades at $3.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPC currently has a P/E ratio of -0.69, whereas CRON's P/E ratio is 29.44. In terms of profitability, UPC's ROE is -0.03%, compared to CRON's ROE of +0.06%. Regarding short-term risk, UPC is more volatile compared to CRON. This indicates higher risk in terms of short-term price fluctuations for UPC.Check CRON's competition here
Pacira BioSciences, Inc. (NASDAQ: PCRX)
UPC vs PCRX Comparison August 2026
Universe Pharmaceuticals Inc. (NASDAQ: UPC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPC stands at 3.5M. In comparison, PCRX has a market cap of 984.2M. Regarding current trading prices, UPC is priced at $5.56 on the NASDAQ, while PCRX trades at $25.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPC currently has a P/E ratio of -0.69, whereas PCRX's P/E ratio is 9.62. In terms of profitability, UPC's ROE is -0.03%, compared to PCRX's ROE of +0.02%. Regarding short-term risk, UPC is more volatile compared to PCRX. This indicates higher risk in terms of short-term price fluctuations for UPC.Check PCRX's competition here
Collegium Pharmaceutical, Inc. (NASDAQ: COLL)
UPC vs COLL Comparison August 2026
Universe Pharmaceuticals Inc. (NASDAQ: UPC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPC stands at 3.5M. In comparison, COLL has a market cap of 955.8M. Regarding current trading prices, UPC is priced at $5.56 on the NASDAQ, while COLL trades at $29.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPC currently has a P/E ratio of -0.69, whereas COLL's P/E ratio is 3.70. In terms of profitability, UPC's ROE is -0.03%, compared to COLL's ROE of +0.16%. Regarding short-term risk, UPC is more volatile compared to COLL. This indicates higher risk in terms of short-term price fluctuations for UPC.Check COLL's competition here
PetIQ, Inc. (NASDAQ: PETQ)
UPC vs PETQ Comparison August 2026
Universe Pharmaceuticals Inc. (NASDAQ: UPC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPC stands at 3.5M. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, UPC is priced at $5.56 on the NASDAQ, while PETQ trades at $30.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPC currently has a P/E ratio of -0.69, whereas PETQ's P/E ratio is 83.73. In terms of profitability, UPC's ROE is -0.03%, compared to PETQ's ROE of +0.01%. Regarding short-term risk, UPC is more volatile compared to PETQ. This indicates higher risk in terms of short-term price fluctuations for UPC.Check PETQ's competition here
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH)
UPC vs AMPH Comparison August 2026
Universe Pharmaceuticals Inc. (NASDAQ: UPC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPC stands at 3.5M. In comparison, AMPH has a market cap of 916.3M. Regarding current trading prices, UPC is priced at $5.56 on the NASDAQ, while AMPH trades at $20.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPC currently has a P/E ratio of -0.69, whereas AMPH's P/E ratio is 7.09. In terms of profitability, UPC's ROE is -0.03%, compared to AMPH's ROE of +0.10%. Regarding short-term risk, UPC is more volatile compared to AMPH. This indicates higher risk in terms of short-term price fluctuations for UPC.Check AMPH's competition here
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD)
UPC vs IRWD Comparison August 2026
Universe Pharmaceuticals Inc. (NASDAQ: UPC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPC stands at 3.5M. In comparison, IRWD has a market cap of 711.1M. Regarding current trading prices, UPC is priced at $5.56 on the NASDAQ, while IRWD trades at $4.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPC currently has a P/E ratio of -0.69, whereas IRWD's P/E ratio is 5.54. In terms of profitability, UPC's ROE is -0.03%, compared to IRWD's ROE of -0.57%. Regarding short-term risk, UPC is more volatile compared to IRWD. This indicates higher risk in terms of short-term price fluctuations for UPC.Check IRWD's competition here
Evotec SE (NASDAQ: EVO)
UPC vs EVO Comparison August 2026
Universe Pharmaceuticals Inc. (NASDAQ: UPC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPC stands at 3.5M. In comparison, EVO has a market cap of 710.5M. Regarding current trading prices, UPC is priced at $5.56 on the NASDAQ, while EVO trades at $2.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPC currently has a P/E ratio of -0.69, whereas EVO's P/E ratio is -2.82. In terms of profitability, UPC's ROE is -0.03%, compared to EVO's ROE of -0.24%. Regarding short-term risk, UPC is more volatile compared to EVO. This indicates higher risk in terms of short-term price fluctuations for UPC.Check EVO's competition here
BioDelivery Sciences International, Inc. (NASDAQ: BDSI)
UPC vs BDSI Comparison August 2026
Universe Pharmaceuticals Inc. (NASDAQ: UPC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPC stands at 3.5M. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, UPC is priced at $5.56 on the NASDAQ, while BDSI trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPC currently has a P/E ratio of -0.69, whereas BDSI's P/E ratio is 6.82. In terms of profitability, UPC's ROE is -0.03%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, UPC is more volatile compared to BDSI. This indicates higher risk in terms of short-term price fluctuations for UPC.Check BDSI's competition here
Tilray Brands, Inc. (NASDAQ: TLRY)
UPC vs TLRY Comparison August 2026
Universe Pharmaceuticals Inc. (NASDAQ: UPC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPC stands at 3.5M. In comparison, TLRY has a market cap of 511.1M. Regarding current trading prices, UPC is priced at $5.56 on the NASDAQ, while TLRY trades at $4.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPC currently has a P/E ratio of -0.69, whereas TLRY's P/E ratio is -7.21. In terms of profitability, UPC's ROE is -0.03%, compared to TLRY's ROE of -0.08%. Regarding short-term risk, UPC is more volatile compared to TLRY. This indicates higher risk in terms of short-term price fluctuations for UPC.Check TLRY's competition here
Evolus, Inc. (NASDAQ: EOLS)
UPC vs EOLS Comparison August 2026
Universe Pharmaceuticals Inc. (NASDAQ: UPC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPC stands at 3.5M. In comparison, EOLS has a market cap of 499.8M. Regarding current trading prices, UPC is priced at $5.56 on the NASDAQ, while EOLS trades at $7.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPC currently has a P/E ratio of -0.69, whereas EOLS's P/E ratio is -24.04. In terms of profitability, UPC's ROE is -0.03%, compared to EOLS's ROE of +1.23%. Regarding short-term risk, UPC is more volatile compared to EOLS. This indicates higher risk in terms of short-term price fluctuations for UPC.Check EOLS's competition here
Aquestive Therapeutics, Inc. (NASDAQ: AQST)
UPC vs AQST Comparison August 2026
Universe Pharmaceuticals Inc. (NASDAQ: UPC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPC stands at 3.5M. In comparison, AQST has a market cap of 494.3M. Regarding current trading prices, UPC is priced at $5.56 on the NASDAQ, while AQST trades at $3.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPC currently has a P/E ratio of -0.69, whereas AQST's P/E ratio is -6.46. In terms of profitability, UPC's ROE is -0.03%, compared to AQST's ROE of +1.91%. Regarding short-term risk, UPC is more volatile compared to AQST. This indicates higher risk in terms of short-term price fluctuations for UPC.Check AQST's competition here
Kamada Ltd. (NASDAQ: KMDA)
UPC vs KMDA Comparison August 2026
Universe Pharmaceuticals Inc. (NASDAQ: UPC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPC stands at 3.5M. In comparison, KMDA has a market cap of 419.4M. Regarding current trading prices, UPC is priced at $5.56 on the NASDAQ, while KMDA trades at $7.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPC currently has a P/E ratio of -0.69, whereas KMDA's P/E ratio is 20.77. In terms of profitability, UPC's ROE is -0.03%, compared to KMDA's ROE of +0.08%. Regarding short-term risk, UPC is more volatile compared to KMDA. This indicates higher risk in terms of short-term price fluctuations for UPC.Check KMDA's competition here
Canopy Growth Corporation (NASDAQ: CGC)
UPC vs CGC Comparison August 2026
Universe Pharmaceuticals Inc. (NASDAQ: UPC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPC stands at 3.5M. In comparison, CGC has a market cap of 409.5M. Regarding current trading prices, UPC is priced at $5.56 on the NASDAQ, while CGC trades at $0.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPC currently has a P/E ratio of -0.69, whereas CGC's P/E ratio is -0.58. In terms of profitability, UPC's ROE is -0.03%, compared to CGC's ROE of -0.31%. Regarding short-term risk, UPC is more volatile compared to CGC. This indicates higher risk in terms of short-term price fluctuations for UPC.Check CGC's competition here
Alpha Teknova, Inc. (NASDAQ: TKNO)
UPC vs TKNO Comparison August 2026
Universe Pharmaceuticals Inc. (NASDAQ: UPC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPC stands at 3.5M. In comparison, TKNO has a market cap of 346.3M. Regarding current trading prices, UPC is priced at $5.56 on the NASDAQ, while TKNO trades at $6.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPC currently has a P/E ratio of -0.69, whereas TKNO's P/E ratio is -20.84. In terms of profitability, UPC's ROE is -0.03%, compared to TKNO's ROE of -0.25%. Regarding short-term risk, UPC is more volatile compared to TKNO. This indicates higher risk in terms of short-term price fluctuations for UPC.Check TKNO's competition here
Alimera Sciences, Inc. (NASDAQ: ALIM)
UPC vs ALIM Comparison August 2026
Universe Pharmaceuticals Inc. (NASDAQ: UPC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPC stands at 3.5M. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, UPC is priced at $5.56 on the NASDAQ, while ALIM trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPC currently has a P/E ratio of -0.69, whereas ALIM's P/E ratio is 5.28. In terms of profitability, UPC's ROE is -0.03%, compared to ALIM's ROE of -1.59%. Regarding short-term risk, UPC is more volatile compared to ALIM. This indicates higher risk in terms of short-term price fluctuations for UPC.Check ALIM's competition here
Landec Corporation (NASDAQ: LNDC)
UPC vs LNDC Comparison August 2026
Universe Pharmaceuticals Inc. (NASDAQ: UPC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPC stands at 3.5M. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, UPC is priced at $5.56 on the NASDAQ, while LNDC trades at $8.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPC currently has a P/E ratio of -0.69, whereas LNDC's P/E ratio is -4.04. In terms of profitability, UPC's ROE is -0.03%, compared to LNDC's ROE of +6.44%. Regarding short-term risk, UPC is more volatile compared to LNDC. This indicates higher risk in terms of short-term price fluctuations for UPC.Check LNDC's competition here
Embecta Corp. (NASDAQ: EMBC)
UPC vs EMBC Comparison August 2026
Universe Pharmaceuticals Inc. (NASDAQ: UPC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPC stands at 3.5M. In comparison, EMBC has a market cap of 262.2M. Regarding current trading prices, UPC is priced at $5.56 on the NASDAQ, while EMBC trades at $4.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPC currently has a P/E ratio of -0.69, whereas EMBC's P/E ratio is 1.70. In terms of profitability, UPC's ROE is -0.03%, compared to EMBC's ROE of -0.14%. Regarding short-term risk, UPC is less volatile compared to EMBC. This indicates lower risk in terms of short-term price fluctuations for UPC.Check EMBC's competition here
Organogenesis Holdings Inc. (NASDAQ: ORGO)
UPC vs ORGO Comparison August 2026
Universe Pharmaceuticals Inc. (NASDAQ: UPC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPC stands at 3.5M. In comparison, ORGO has a market cap of 239.3M. Regarding current trading prices, UPC is priced at $5.56 on the NASDAQ, while ORGO trades at $1.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPC currently has a P/E ratio of -0.69, whereas ORGO's P/E ratio is 62.00. In terms of profitability, UPC's ROE is -0.03%, compared to ORGO's ROE of -0.27%. Regarding short-term risk, UPC is less volatile compared to ORGO. This indicates lower risk in terms of short-term price fluctuations for UPC.Check ORGO's competition here
Shineco, Inc. (NASDAQ: TYHT)
UPC vs TYHT Comparison August 2026
Universe Pharmaceuticals Inc. (NASDAQ: UPC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPC stands at 3.5M. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, UPC is priced at $5.56 on the NASDAQ, while TYHT trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPC currently has a P/E ratio of -0.69, whereas TYHT's P/E ratio is -1.61. In terms of profitability, UPC's ROE is -0.03%, compared to TYHT's ROE of -0.57%. Regarding short-term risk, UPC is more volatile compared to TYHT. This indicates higher risk in terms of short-term price fluctuations for UPC.Check TYHT's competition here
SIGA Technologies, Inc. (NASDAQ: SIGA)
UPC vs SIGA Comparison August 2026
Universe Pharmaceuticals Inc. (NASDAQ: UPC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPC stands at 3.5M. In comparison, SIGA has a market cap of 218.8M. Regarding current trading prices, UPC is priced at $5.56 on the NASDAQ, while SIGA trades at $3.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPC currently has a P/E ratio of -0.69, whereas SIGA's P/E ratio is 11.30. In terms of profitability, UPC's ROE is -0.03%, compared to SIGA's ROE of -0.02%. Regarding short-term risk, UPC is more volatile compared to SIGA. This indicates higher risk in terms of short-term price fluctuations for UPC.Check SIGA's competition here
Lifecore Biomedical, Inc. (NASDAQ: LFCR)
UPC vs LFCR Comparison August 2026
Universe Pharmaceuticals Inc. (NASDAQ: UPC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPC stands at 3.5M. In comparison, LFCR has a market cap of 187.9M. Regarding current trading prices, UPC is priced at $5.56 on the NASDAQ, while LFCR trades at $5.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPC currently has a P/E ratio of -0.69, whereas LFCR's P/E ratio is -4.68. In terms of profitability, UPC's ROE is -0.03%, compared to LFCR's ROE of -1.95%. Regarding short-term risk, UPC is more volatile compared to LFCR. This indicates higher risk in terms of short-term price fluctuations for UPC.Check LFCR's competition here
Aurora Cannabis Inc. (NASDAQ: ACB)
UPC vs ACB Comparison August 2026
Universe Pharmaceuticals Inc. (NASDAQ: UPC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPC stands at 3.5M. In comparison, ACB has a market cap of 185.2M. Regarding current trading prices, UPC is priced at $5.56 on the NASDAQ, while ACB trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPC currently has a P/E ratio of -0.69, whereas ACB's P/E ratio is -6.10. In terms of profitability, UPC's ROE is -0.03%, compared to ACB's ROE of -0.21%. Regarding short-term risk, UPC is more volatile compared to ACB. This indicates higher risk in terms of short-term price fluctuations for UPC.Check ACB's competition here
Recro Pharma, Inc. (NASDAQ: REPH)
UPC vs REPH Comparison August 2026
Universe Pharmaceuticals Inc. (NASDAQ: UPC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPC stands at 3.5M. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, UPC is priced at $5.56 on the NASDAQ, while REPH trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPC currently has a P/E ratio of -0.69, whereas REPH's P/E ratio is -8.04. In terms of profitability, UPC's ROE is -0.03%, compared to REPH's ROE of -0.22%. Regarding short-term risk, UPC is more volatile compared to REPH. This indicates higher risk in terms of short-term price fluctuations for UPC.Check REPH's competition here
Journey Medical Corporation (NASDAQ: DERM)
UPC vs DERM Comparison August 2026
Universe Pharmaceuticals Inc. (NASDAQ: UPC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPC stands at 3.5M. In comparison, DERM has a market cap of 177M. Regarding current trading prices, UPC is priced at $5.56 on the NASDAQ, while DERM trades at $6.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPC currently has a P/E ratio of -0.69, whereas DERM's P/E ratio is -17.38. In terms of profitability, UPC's ROE is -0.03%, compared to DERM's ROE of -0.36%. Regarding short-term risk, UPC is more volatile compared to DERM. This indicates higher risk in terms of short-term price fluctuations for UPC.Check DERM's competition here
Cardiol Therapeutics Inc. (NASDAQ: CRDL)
UPC vs CRDL Comparison August 2026
Universe Pharmaceuticals Inc. (NASDAQ: UPC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPC stands at 3.5M. In comparison, CRDL has a market cap of 163.7M. Regarding current trading prices, UPC is priced at $5.56 on the NASDAQ, while CRDL trades at $1.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPC currently has a P/E ratio of -0.69, whereas CRDL's P/E ratio is -5.05. In terms of profitability, UPC's ROE is -0.03%, compared to CRDL's ROE of -2.29%. Regarding short-term risk, UPC is more volatile compared to CRDL. This indicates higher risk in terms of short-term price fluctuations for UPC.Check CRDL's competition here
Theratechnologies Inc. (NASDAQ: THTX)
UPC vs THTX Comparison August 2026
Universe Pharmaceuticals Inc. (NASDAQ: UPC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPC stands at 3.5M. In comparison, THTX has a market cap of 155.9M. Regarding current trading prices, UPC is priced at $5.56 on the NASDAQ, while THTX trades at $3.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPC currently has a P/E ratio of -0.69, whereas THTX's P/E ratio is -28.83. In terms of profitability, UPC's ROE is -0.03%, compared to THTX's ROE of +0.17%. Regarding short-term risk, UPC is more volatile compared to THTX. This indicates higher risk in terms of short-term price fluctuations for UPC.Check THTX's competition here
Assertio Holdings, Inc. (NASDAQ: ASRT)
UPC vs ASRT Comparison August 2026
Universe Pharmaceuticals Inc. (NASDAQ: UPC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPC stands at 3.5M. In comparison, ASRT has a market cap of 151.9M. Regarding current trading prices, UPC is priced at $5.56 on the NASDAQ, while ASRT trades at $23.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPC currently has a P/E ratio of -0.69, whereas ASRT's P/E ratio is -7.10. In terms of profitability, UPC's ROE is -0.03%, compared to ASRT's ROE of -0.39%. Regarding short-term risk, UPC is more volatile compared to ASRT. This indicates higher risk in terms of short-term price fluctuations for UPC.Check ASRT's competition here
Organigram Global Inc. (NASDAQ: OGI)
UPC vs OGI Comparison August 2026
Universe Pharmaceuticals Inc. (NASDAQ: UPC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPC stands at 3.5M. In comparison, OGI has a market cap of 139.4M. Regarding current trading prices, UPC is priced at $5.56 on the NASDAQ, while OGI trades at $0.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPC currently has a P/E ratio of -0.69, whereas OGI's P/E ratio is -3.81. In terms of profitability, UPC's ROE is -0.03%, compared to OGI's ROE of -0.07%. Regarding short-term risk, UPC is more volatile compared to OGI. This indicates higher risk in terms of short-term price fluctuations for UPC.Check OGI's competition here
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX)
UPC vs CPIX Comparison August 2026
Universe Pharmaceuticals Inc. (NASDAQ: UPC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPC stands at 3.5M. In comparison, CPIX has a market cap of 116.9M. Regarding current trading prices, UPC is priced at $5.56 on the NASDAQ, while CPIX trades at $7.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPC currently has a P/E ratio of -0.69, whereas CPIX's P/E ratio is -19.50. In terms of profitability, UPC's ROE is -0.03%, compared to CPIX's ROE of -0.47%. Regarding short-term risk, UPC is more volatile compared to CPIX. This indicates higher risk in terms of short-term price fluctuations for UPC.Check CPIX's competition here
Societal CDMO, Inc. (NASDAQ: SCTL)
UPC vs SCTL Comparison August 2026
Universe Pharmaceuticals Inc. (NASDAQ: UPC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPC stands at 3.5M. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, UPC is priced at $5.56 on the NASDAQ, while SCTL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPC currently has a P/E ratio of -0.69, whereas SCTL's P/E ratio is -7.86. In terms of profitability, UPC's ROE is -0.03%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, UPC is more volatile compared to SCTL. This indicates higher risk in terms of short-term price fluctuations for UPC.Check SCTL's competition here
Procaps Group S.A. (NASDAQ: PROC)
UPC vs PROC Comparison August 2026
Universe Pharmaceuticals Inc. (NASDAQ: UPC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPC stands at 3.5M. In comparison, PROC has a market cap of 102.1M. Regarding current trading prices, UPC is priced at $5.56 on the NASDAQ, while PROC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPC currently has a P/E ratio of -0.69, whereas PROC's P/E ratio is 1.53. In terms of profitability, UPC's ROE is -0.03%, compared to PROC's ROE of -2.22%. Regarding short-term risk, UPC is more volatile compared to PROC. This indicates higher risk in terms of short-term price fluctuations for UPC.Check PROC's competition here
OptiNose, Inc. (NASDAQ: OPTN)
UPC vs OPTN Comparison August 2026
Universe Pharmaceuticals Inc. (NASDAQ: UPC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPC stands at 3.5M. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, UPC is priced at $5.56 on the NASDAQ, while OPTN trades at $9.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPC currently has a P/E ratio of -0.69, whereas OPTN's P/E ratio is -4.42. In terms of profitability, UPC's ROE is -0.03%, compared to OPTN's ROE of +0.34%. Regarding short-term risk, UPC is more volatile compared to OPTN. This indicates higher risk in terms of short-term price fluctuations for UPC.Check OPTN's competition here
Zomedica Corp. (AMEX: ZOM)
UPC vs ZOM Comparison August 2026
Universe Pharmaceuticals Inc. (NASDAQ: UPC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPC stands at 3.5M. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, UPC is priced at $5.56 on the NASDAQ, while ZOM trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPC currently has a P/E ratio of -0.69, whereas ZOM's P/E ratio is -1.62. In terms of profitability, UPC's ROE is -0.03%, compared to ZOM's ROE of -0.17%. Regarding short-term risk, UPC is more volatile compared to ZOM. This indicates higher risk in terms of short-term price fluctuations for UPC.Check ZOM's competition here
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT)
UPC vs ZYBT Comparison August 2026
Universe Pharmaceuticals Inc. (NASDAQ: UPC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPC stands at 3.5M. In comparison, ZYBT has a market cap of 89.6M. Regarding current trading prices, UPC is priced at $5.56 on the NASDAQ, while ZYBT trades at $1.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPC currently has a P/E ratio of -0.69, whereas ZYBT's P/E ratio is -8.59. In terms of profitability, UPC's ROE is -0.03%, compared to ZYBT's ROE of -0.27%. Regarding short-term risk, UPC is less volatile compared to ZYBT. This indicates lower risk in terms of short-term price fluctuations for UPC.Check ZYBT's competition here
Upexi, Inc. (NASDAQ: GRVI)
UPC vs GRVI Comparison August 2026
Universe Pharmaceuticals Inc. (NASDAQ: UPC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPC stands at 3.5M. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, UPC is priced at $5.56 on the NASDAQ, while GRVI trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPC currently has a P/E ratio of -0.69, whereas GRVI's P/E ratio is 26.05. In terms of profitability, UPC's ROE is -0.03%, compared to GRVI's ROE of -2.54%. Regarding short-term risk, UPC is more volatile compared to GRVI. This indicates higher risk in terms of short-term price fluctuations for UPC.Check GRVI's competition here
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE)
UPC vs ZYNE Comparison August 2026
Universe Pharmaceuticals Inc. (NASDAQ: UPC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPC stands at 3.5M. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, UPC is priced at $5.56 on the NASDAQ, while ZYNE trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPC currently has a P/E ratio of -0.69, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, UPC's ROE is -0.03%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, UPC is more volatile compared to ZYNE. This indicates higher risk in terms of short-term price fluctuations for UPC.Check ZYNE's competition here
Silver Spike Investment Corp. (NASDAQ: SSIC)
UPC vs SSIC Comparison August 2026
Universe Pharmaceuticals Inc. (NASDAQ: UPC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPC stands at 3.5M. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, UPC is priced at $5.56 on the NASDAQ, while SSIC trades at $10.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPC currently has a P/E ratio of -0.69, whereas SSIC's P/E ratio is 11.93. In terms of profitability, UPC's ROE is -0.03%, compared to SSIC's ROE of +0.00%. Regarding short-term risk, UPC is more volatile compared to SSIC. This indicates higher risk in terms of short-term price fluctuations for UPC.Check SSIC's competition here
The Valens Company Inc. (NASDAQ: VLNS)
UPC vs VLNS Comparison August 2026
Universe Pharmaceuticals Inc. (NASDAQ: UPC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPC stands at 3.5M. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, UPC is priced at $5.56 on the NASDAQ, while VLNS trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPC currently has a P/E ratio of -0.69, whereas VLNS's P/E ratio is -1.03. In terms of profitability, UPC's ROE is -0.03%, compared to VLNS's ROE of N/A. Regarding short-term risk, UPC is more volatile compared to VLNS. This indicates higher risk in terms of short-term price fluctuations for UPC.Check VLNS's competition here
BGM Group Ltd. (NASDAQ: BGM)
UPC vs BGM Comparison August 2026
Universe Pharmaceuticals Inc. (NASDAQ: UPC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPC stands at 3.5M. In comparison, BGM has a market cap of 60.3M. Regarding current trading prices, UPC is priced at $5.56 on the NASDAQ, while BGM trades at $0.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPC currently has a P/E ratio of -0.69, whereas BGM's P/E ratio is -1.04. In terms of profitability, UPC's ROE is -0.03%, compared to BGM's ROE of -0.07%. Regarding short-term risk, UPC is more volatile compared to BGM. This indicates higher risk in terms of short-term price fluctuations for UPC.Check BGM's competition here
DURECT Corporation (NASDAQ: DRRX)
UPC vs DRRX Comparison August 2026
Universe Pharmaceuticals Inc. (NASDAQ: UPC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPC stands at 3.5M. In comparison, DRRX has a market cap of 59.3M. Regarding current trading prices, UPC is priced at $5.56 on the NASDAQ, while DRRX trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPC currently has a P/E ratio of -0.69, whereas DRRX's P/E ratio is -4.44. In terms of profitability, UPC's ROE is -0.03%, compared to DRRX's ROE of -1.40%. Regarding short-term risk, UPC is more volatile compared to DRRX. This indicates higher risk in terms of short-term price fluctuations for UPC.Check DRRX's competition here
InterCure Ltd. (NASDAQ: INCR)
UPC vs INCR Comparison August 2026
Universe Pharmaceuticals Inc. (NASDAQ: UPC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPC stands at 3.5M. In comparison, INCR has a market cap of 58M. Regarding current trading prices, UPC is priced at $5.56 on the NASDAQ, while INCR trades at $0.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPC currently has a P/E ratio of -0.69, whereas INCR's P/E ratio is -2.26. In terms of profitability, UPC's ROE is -0.03%, compared to INCR's ROE of -0.09%. Regarding short-term risk, UPC is more volatile compared to INCR. This indicates higher risk in terms of short-term price fluctuations for UPC.Check INCR's competition here
Jupiter Wellness, Inc. (NASDAQ: JUPW)
UPC vs JUPW Comparison August 2026
Universe Pharmaceuticals Inc. (NASDAQ: UPC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPC stands at 3.5M. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, UPC is priced at $5.56 on the NASDAQ, while JUPW trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPC currently has a P/E ratio of -0.69, whereas JUPW's P/E ratio is -2.41. In terms of profitability, UPC's ROE is -0.03%, compared to JUPW's ROE of -1.94%. Regarding short-term risk, UPC is similarly volatile compared to JUPW. This indicates similar risk in terms of short-term price fluctuations for UPC.Check JUPW's competition here
Qilian International Holding Group Limited (NASDAQ: QLI)
UPC vs QLI Comparison August 2026
Universe Pharmaceuticals Inc. (NASDAQ: UPC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPC stands at 3.5M. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, UPC is priced at $5.56 on the NASDAQ, while QLI trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPC currently has a P/E ratio of -0.69, whereas QLI's P/E ratio is -4.92. In terms of profitability, UPC's ROE is -0.03%, compared to QLI's ROE of -0.16%. Regarding short-term risk, UPC is more volatile compared to QLI. This indicates higher risk in terms of short-term price fluctuations for UPC.Check QLI's competition here
HEXO Corp. (NASDAQ: HEXO)
UPC vs HEXO Comparison August 2026
Universe Pharmaceuticals Inc. (NASDAQ: UPC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPC stands at 3.5M. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, UPC is priced at $5.56 on the NASDAQ, while HEXO trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPC currently has a P/E ratio of -0.69, whereas HEXO's P/E ratio is -0.26. In terms of profitability, UPC's ROE is -0.03%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, UPC is more volatile compared to HEXO. This indicates higher risk in terms of short-term price fluctuations for UPC.Check HEXO's competition here
Talphera, Inc. (NASDAQ: TLPH)
UPC vs TLPH Comparison August 2026
Universe Pharmaceuticals Inc. (NASDAQ: UPC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPC stands at 3.5M. In comparison, TLPH has a market cap of 29.3M. Regarding current trading prices, UPC is priced at $5.56 on the NASDAQ, while TLPH trades at $1.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPC currently has a P/E ratio of -0.69, whereas TLPH's P/E ratio is -4.61. In terms of profitability, UPC's ROE is -0.03%, compared to TLPH's ROE of -0.93%. Regarding short-term risk, UPC is more volatile compared to TLPH. This indicates higher risk in terms of short-term price fluctuations for UPC.Check TLPH's competition here
Rockwell Medical, Inc. (NASDAQ: RMTI)
UPC vs RMTI Comparison August 2026
Universe Pharmaceuticals Inc. (NASDAQ: UPC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPC stands at 3.5M. In comparison, RMTI has a market cap of 28.5M. Regarding current trading prices, UPC is priced at $5.56 on the NASDAQ, while RMTI trades at $7.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPC currently has a P/E ratio of -0.69, whereas RMTI's P/E ratio is -6.89. In terms of profitability, UPC's ROE is -0.03%, compared to RMTI's ROE of -0.15%. Regarding short-term risk, UPC is more volatile compared to RMTI. This indicates higher risk in terms of short-term price fluctuations for UPC.Check RMTI's competition here
Aytu BioPharma, Inc. (NASDAQ: AYTU)
UPC vs AYTU Comparison August 2026
Universe Pharmaceuticals Inc. (NASDAQ: UPC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPC stands at 3.5M. In comparison, AYTU has a market cap of 25.3M. Regarding current trading prices, UPC is priced at $5.56 on the NASDAQ, while AYTU trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPC currently has a P/E ratio of -0.69, whereas AYTU's P/E ratio is -1.23. In terms of profitability, UPC's ROE is -0.03%, compared to AYTU's ROE of -1.49%. Regarding short-term risk, UPC is more volatile compared to AYTU. This indicates higher risk in terms of short-term price fluctuations for UPC.Check AYTU's competition here
TherapeuticsMD, Inc. (NASDAQ: TXMD)
UPC vs TXMD Comparison August 2026
Universe Pharmaceuticals Inc. (NASDAQ: UPC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPC stands at 3.5M. In comparison, TXMD has a market cap of 24M. Regarding current trading prices, UPC is priced at $5.56 on the NASDAQ, while TXMD trades at $2.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPC currently has a P/E ratio of -0.69, whereas TXMD's P/E ratio is 105.45. In terms of profitability, UPC's ROE is -0.03%, compared to TXMD's ROE of +0.01%. Regarding short-term risk, UPC is more volatile compared to TXMD. This indicates higher risk in terms of short-term price fluctuations for UPC.Check TXMD's competition here
Cyclo Therapeutics, Inc. (NASDAQ: CYTH)
UPC vs CYTH Comparison August 2026
Universe Pharmaceuticals Inc. (NASDAQ: UPC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPC stands at 3.5M. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, UPC is priced at $5.56 on the NASDAQ, while CYTH trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPC currently has a P/E ratio of -0.69, whereas CYTH's P/E ratio is -0.80. In terms of profitability, UPC's ROE is -0.03%, compared to CYTH's ROE of -7.30%. Regarding short-term risk, UPC is more volatile compared to CYTH. This indicates higher risk in terms of short-term price fluctuations for UPC.Check CYTH's competition here
Evoke Pharma, Inc. (NASDAQ: EVOK)
UPC vs EVOK Comparison August 2026
Universe Pharmaceuticals Inc. (NASDAQ: UPC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPC stands at 3.5M. In comparison, EVOK has a market cap of 18.9M. Regarding current trading prices, UPC is priced at $5.56 on the NASDAQ, while EVOK trades at $11.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPC currently has a P/E ratio of -0.69, whereas EVOK's P/E ratio is -7.97. In terms of profitability, UPC's ROE is -0.03%, compared to EVOK's ROE of -0.89%. Regarding short-term risk, UPC is more volatile compared to EVOK. This indicates higher risk in terms of short-term price fluctuations for UPC.Check EVOK's competition here
Biofrontera Inc. (NASDAQ: BFRIW)
UPC vs BFRIW Comparison August 2026
Universe Pharmaceuticals Inc. (NASDAQ: UPC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPC stands at 3.5M. In comparison, BFRIW has a market cap of 17M. Regarding current trading prices, UPC is priced at $5.56 on the NASDAQ, while BFRIW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPC currently has a P/E ratio of -0.69, whereas BFRIW's P/E ratio is -0.03. In terms of profitability, UPC's ROE is -0.03%, compared to BFRIW's ROE of -4.77%. Regarding short-term risk, UPC is less volatile compared to BFRIW. This indicates lower risk in terms of short-term price fluctuations for UPC.Check BFRIW's competition here
Optimi Health Corp. (NASDAQ: OPTH)
UPC vs OPTH Comparison August 2026
Universe Pharmaceuticals Inc. (NASDAQ: UPC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPC stands at 3.5M. In comparison, OPTH has a market cap of 16.3M. Regarding current trading prices, UPC is priced at $5.56 on the NASDAQ, while OPTH trades at $5.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPC currently has a P/E ratio of -0.69, whereas OPTH's P/E ratio is -18.56. In terms of profitability, UPC's ROE is -0.03%, compared to OPTH's ROE of -0.94%. Regarding short-term risk, UPC is more volatile compared to OPTH. This indicates higher risk in terms of short-term price fluctuations for UPC.Check OPTH's competition here
AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX)
UPC vs ACRX Comparison August 2026
Universe Pharmaceuticals Inc. (NASDAQ: UPC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPC stands at 3.5M. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, UPC is priced at $5.56 on the NASDAQ, while ACRX trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPC currently has a P/E ratio of -0.69, whereas ACRX's P/E ratio is -0.31. In terms of profitability, UPC's ROE is -0.03%, compared to ACRX's ROE of -0.93%. Regarding short-term risk, UPC is more volatile compared to ACRX. This indicates higher risk in terms of short-term price fluctuations for UPC.Check ACRX's competition here
Cosmos Health Inc. (NASDAQ: COSM)
UPC vs COSM Comparison August 2026
Universe Pharmaceuticals Inc. (NASDAQ: UPC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPC stands at 3.5M. In comparison, COSM has a market cap of 12.7M. Regarding current trading prices, UPC is priced at $5.56 on the NASDAQ, while COSM trades at $0.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPC currently has a P/E ratio of -0.69, whereas COSM's P/E ratio is -0.38. In terms of profitability, UPC's ROE is -0.03%, compared to COSM's ROE of -0.96%. Regarding short-term risk, UPC is more volatile compared to COSM. This indicates higher risk in terms of short-term price fluctuations for UPC.Check COSM's competition here
Agile Therapeutics, Inc. (NASDAQ: AGRX)
UPC vs AGRX Comparison August 2026
Universe Pharmaceuticals Inc. (NASDAQ: UPC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPC stands at 3.5M. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, UPC is priced at $5.56 on the NASDAQ, while AGRX trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPC currently has a P/E ratio of -0.69, whereas AGRX's P/E ratio is -0.89. In terms of profitability, UPC's ROE is -0.03%, compared to AGRX's ROE of +1.32%. Regarding short-term risk, UPC is more volatile compared to AGRX. This indicates higher risk in terms of short-term price fluctuations for UPC.Check AGRX's competition here
Neoleukin Therapeutics, Inc. (NASDAQ: NLTX)
UPC vs NLTX Comparison August 2026
Universe Pharmaceuticals Inc. (NASDAQ: UPC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPC stands at 3.5M. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, UPC is priced at $5.56 on the NASDAQ, while NLTX trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPC currently has a P/E ratio of -0.69, whereas NLTX's P/E ratio is -0.28. In terms of profitability, UPC's ROE is -0.03%, compared to NLTX's ROE of -0.38%. Regarding short-term risk, UPC is more volatile compared to NLTX. This indicates higher risk in terms of short-term price fluctuations for UPC.Check NLTX's competition here
Lannett Company, Inc. (NYSE: LCI)
UPC vs LCI Comparison August 2026
Universe Pharmaceuticals Inc. (NASDAQ: UPC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPC stands at 3.5M. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, UPC is priced at $5.56 on the NASDAQ, while LCI trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPC currently has a P/E ratio of -0.69, whereas LCI's P/E ratio is -0.04. In terms of profitability, UPC's ROE is -0.03%, compared to LCI's ROE of +1.66%. Regarding short-term risk, UPC is more volatile compared to LCI. This indicates higher risk in terms of short-term price fluctuations for UPC.Check LCI's competition here
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP)
UPC vs ADMP Comparison August 2026
Universe Pharmaceuticals Inc. (NASDAQ: UPC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPC stands at 3.5M. In comparison, ADMP has a market cap of 7.3M. Regarding current trading prices, UPC is priced at $5.56 on the NASDAQ, while ADMP trades at $0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPC currently has a P/E ratio of -0.69, whereas ADMP's P/E ratio is -0.08. In terms of profitability, UPC's ROE is -0.03%, compared to ADMP's ROE of -2.09%. Regarding short-term risk, UPC is more volatile compared to ADMP. This indicates higher risk in terms of short-term price fluctuations for UPC.Check ADMP's competition here
cbdMD, Inc. (AMEX: YCBD)
UPC vs YCBD Comparison August 2026
Universe Pharmaceuticals Inc. (NASDAQ: UPC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPC stands at 3.5M. In comparison, YCBD has a market cap of 5.9M. Regarding current trading prices, UPC is priced at $5.56 on the NASDAQ, while YCBD trades at $0.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPC currently has a P/E ratio of -0.69, whereas YCBD's P/E ratio is -1.38. In terms of profitability, UPC's ROE is -0.03%, compared to YCBD's ROE of -0.34%. Regarding short-term risk, UPC is more volatile compared to YCBD. This indicates higher risk in terms of short-term price fluctuations for UPC.Check YCBD's competition here
Gelteq Limited Ordinary Shares (NASDAQ: GELS)
UPC vs GELS Comparison August 2026
Universe Pharmaceuticals Inc. (NASDAQ: UPC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPC stands at 3.5M. In comparison, GELS has a market cap of 5M. Regarding current trading prices, UPC is priced at $5.56 on the NASDAQ, while GELS trades at $0.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPC currently has a P/E ratio of -0.69, whereas GELS's P/E ratio is -1.09. In terms of profitability, UPC's ROE is -0.03%, compared to GELS's ROE of -0.25%. Regarding short-term risk, UPC is more volatile compared to GELS. This indicates higher risk in terms of short-term price fluctuations for UPC.Check GELS's competition here
Mallinckrodt plc (AMEX: MNK)
UPC vs MNK Comparison August 2026
Universe Pharmaceuticals Inc. (NASDAQ: UPC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPC stands at 3.5M. In comparison, MNK has a market cap of 4.5M. Regarding current trading prices, UPC is priced at $5.56 on the NASDAQ, while MNK trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPC currently has a P/E ratio of -0.69, whereas MNK's P/E ratio is -0.44. In terms of profitability, UPC's ROE is -0.03%, compared to MNK's ROE of -0.26%. Regarding short-term risk, UPC is less volatile compared to MNK. This indicates lower risk in terms of short-term price fluctuations for UPC.Check MNK's competition here
Flora Growth Corp. (NASDAQ: FLGC)
UPC vs FLGC Comparison August 2026
Universe Pharmaceuticals Inc. (NASDAQ: UPC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPC stands at 3.5M. In comparison, FLGC has a market cap of 4.2M. Regarding current trading prices, UPC is priced at $5.56 on the NASDAQ, while FLGC trades at $7.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPC currently has a P/E ratio of -0.69, whereas FLGC's P/E ratio is -0.19. In terms of profitability, UPC's ROE is -0.03%, compared to FLGC's ROE of -3.03%. Regarding short-term risk, UPC is less volatile compared to FLGC. This indicates lower risk in terms of short-term price fluctuations for UPC.Check FLGC's competition here
China Pharma Holdings, Inc. (AMEX: CPHI)
UPC vs CPHI Comparison August 2026
Universe Pharmaceuticals Inc. (NASDAQ: UPC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPC stands at 3.5M. In comparison, CPHI has a market cap of 3.6M. Regarding current trading prices, UPC is priced at $5.56 on the NASDAQ, while CPHI trades at $1.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPC currently has a P/E ratio of -0.69, whereas CPHI's P/E ratio is -1.76. In terms of profitability, UPC's ROE is -0.03%, compared to CPHI's ROE of -0.19%. Regarding short-term risk, UPC is more volatile compared to CPHI. This indicates higher risk in terms of short-term price fluctuations for UPC.Check CPHI's competition here
Sunshine Biopharma, Inc. (NASDAQ: SBFM)
UPC vs SBFM Comparison August 2026
Universe Pharmaceuticals Inc. (NASDAQ: UPC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPC stands at 3.5M. In comparison, SBFM has a market cap of 2.9M. Regarding current trading prices, UPC is priced at $5.56 on the NASDAQ, while SBFM trades at $1.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPC currently has a P/E ratio of -0.69, whereas SBFM's P/E ratio is -0.20. In terms of profitability, UPC's ROE is -0.03%, compared to SBFM's ROE of -0.26%. Regarding short-term risk, UPC is less volatile compared to SBFM. This indicates lower risk in terms of short-term price fluctuations for UPC.Check SBFM's competition here
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH)
UPC vs SHPH Comparison August 2026
Universe Pharmaceuticals Inc. (NASDAQ: UPC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPC stands at 3.5M. In comparison, SHPH has a market cap of 2.6M. Regarding current trading prices, UPC is priced at $5.56 on the NASDAQ, while SHPH trades at $4.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPC currently has a P/E ratio of -0.69, whereas SHPH's P/E ratio is -0.20. In terms of profitability, UPC's ROE is -0.03%, compared to SHPH's ROE of -4.08%. Regarding short-term risk, UPC is more volatile compared to SHPH. This indicates higher risk in terms of short-term price fluctuations for UPC.Check SHPH's competition here
PLx Pharma Inc. (NASDAQ: PLXP)
UPC vs PLXP Comparison August 2026
Universe Pharmaceuticals Inc. (NASDAQ: UPC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPC stands at 3.5M. In comparison, PLXP has a market cap of 2.5M. Regarding current trading prices, UPC is priced at $5.56 on the NASDAQ, while PLXP trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPC currently has a P/E ratio of -0.69, whereas PLXP's P/E ratio is -0.22. In terms of profitability, UPC's ROE is -0.03%, compared to PLXP's ROE of -1.66%. Regarding short-term risk, UPC is less volatile compared to PLXP. This indicates lower risk in terms of short-term price fluctuations for UPC.Check PLXP's competition here
Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA)
UPC vs SNOA Comparison August 2026
Universe Pharmaceuticals Inc. (NASDAQ: UPC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPC stands at 3.5M. In comparison, SNOA has a market cap of 2.4M. Regarding current trading prices, UPC is priced at $5.56 on the NASDAQ, while SNOA trades at $1.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPC currently has a P/E ratio of -0.69, whereas SNOA's P/E ratio is -1.22. In terms of profitability, UPC's ROE is -0.03%, compared to SNOA's ROE of -0.54%. Regarding short-term risk, UPC is less volatile compared to SNOA. This indicates lower risk in terms of short-term price fluctuations for UPC.Check SNOA's competition here
Athenex, Inc. (NASDAQ: ATNX)
UPC vs ATNX Comparison August 2026
Universe Pharmaceuticals Inc. (NASDAQ: UPC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPC stands at 3.5M. In comparison, ATNX has a market cap of 2.3M. Regarding current trading prices, UPC is priced at $5.56 on the NASDAQ, while ATNX trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPC currently has a P/E ratio of -0.69, whereas ATNX's P/E ratio is -0.02. In terms of profitability, UPC's ROE is -0.03%, compared to ATNX's ROE of +0.22%. Regarding short-term risk, UPC is more volatile compared to ATNX. This indicates higher risk in terms of short-term price fluctuations for UPC.Check ATNX's competition here
Procaps Group, S.A. (NASDAQ: PROCW)
UPC vs PROCW Comparison August 2026
Universe Pharmaceuticals Inc. (NASDAQ: UPC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPC stands at 3.5M. In comparison, PROCW has a market cap of 2M. Regarding current trading prices, UPC is priced at $5.56 on the NASDAQ, while PROCW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPC currently has a P/E ratio of -0.69, whereas PROCW's P/E ratio is N/A. In terms of profitability, UPC's ROE is -0.03%, compared to PROCW's ROE of -2.22%. Regarding short-term risk, UPC is more volatile compared to PROCW. This indicates higher risk in terms of short-term price fluctuations for UPC.Check PROCW's competition here
RedHill Biopharma Ltd. (NASDAQ: RDHL)
UPC vs RDHL Comparison August 2026
Universe Pharmaceuticals Inc. (NASDAQ: UPC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPC stands at 3.5M. In comparison, RDHL has a market cap of 1.9M. Regarding current trading prices, UPC is priced at $5.56 on the NASDAQ, while RDHL trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPC currently has a P/E ratio of -0.69, whereas RDHL's P/E ratio is 0.12. In terms of profitability, UPC's ROE is -0.03%, compared to RDHL's ROE of +57.40%. Regarding short-term risk, UPC is more volatile compared to RDHL. This indicates higher risk in terms of short-term price fluctuations for UPC.Check RDHL's competition here
cbdMD, Inc. (AMEX: YCBD-PA)
UPC vs YCBD-PA Comparison August 2026
Universe Pharmaceuticals Inc. (NASDAQ: UPC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPC stands at 3.5M. In comparison, YCBD-PA has a market cap of 928.2K. Regarding current trading prices, UPC is priced at $5.56 on the NASDAQ, while YCBD-PA trades at $1.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPC currently has a P/E ratio of -0.69, whereas YCBD-PA's P/E ratio is -2.69. In terms of profitability, UPC's ROE is -0.03%, compared to YCBD-PA's ROE of -0.34%. Regarding short-term risk, UPC is less volatile compared to YCBD-PA. This indicates lower risk in terms of short-term price fluctuations for UPC.Check YCBD-PA's competition here
Cyclo Therapeutics, Inc. (NASDAQ: CYTHW)
UPC vs CYTHW Comparison August 2026
Universe Pharmaceuticals Inc. (NASDAQ: UPC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPC stands at 3.5M. In comparison, CYTHW has a market cap of 928K. Regarding current trading prices, UPC is priced at $5.56 on the NASDAQ, while CYTHW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPC currently has a P/E ratio of -0.69, whereas CYTHW's P/E ratio is N/A. In terms of profitability, UPC's ROE is -0.03%, compared to CYTHW's ROE of -7.30%. Regarding short-term risk, UPC is more volatile compared to CYTHW. This indicates higher risk in terms of short-term price fluctuations for UPC.Check CYTHW's competition here
Lucy Scientific Discovery Inc. (NASDAQ: LSDI)
UPC vs LSDI Comparison August 2026
Universe Pharmaceuticals Inc. (NASDAQ: UPC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UPC stands at 3.5M. In comparison, LSDI has a market cap of 906.9K. Regarding current trading prices, UPC is priced at $5.56 on the NASDAQ, while LSDI trades at $0.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UPC currently has a P/E ratio of -0.69, whereas LSDI's P/E ratio is -0.07. In terms of profitability, UPC's ROE is -0.03%, compared to LSDI's ROE of +181.47%. Regarding short-term risk, UPC is less volatile compared to LSDI. This indicates lower risk in terms of short-term price fluctuations for UPC.Check LSDI's competition here